“Too little is known about a molecule’s potential to become a drug when it enters development. Only one in 250 development programs succeed.
Example, almost thirty drugs failed in clinical trials for Alzheimer’s in the last fifteen years. The theory behind most of them has now been dropped for another, which has seen at least one PhIII failure.
For evidence, we trace back to 1976 and the world’s first blockbuster. Since then, the industry has paid insufficient attention to the suitability of molecules chosen to go into development.
We then discuss how outsourcing critical assets resulted in Big Pharma becoming a dried up prune compared to the fulsome plum it used to be.
The effect of these two strategic errors has created the issues we see today, sky-rocketing drug prices, clinical trial failures, $bn for damaging side-effects, me-too drugs, shortages, counterfeiting, price gouging.
It concludes with a call to action for politicians:
“Don’t fight the system, change the rules and the system will change itself”
…and the rule change required is explained.
Click on the link below to learn more: